瑞士儿科个性化研究网络 (SwissPedHealth):一个联合的儿科国家数据流
Rebeca Mozun1, Fabiën N Belle2, Andrea Agostini3
1Department of Intensive Care and Neonatology and Children's Research Center, University Children's Hospital Zürich, Zurich, Switzerland.
BMJ open
|December 26, 2024
概括
瑞士PedHealth网络正在建立一个可持续的基础设施,用于使用标准化临床数据进行儿科研究. 该倡议旨在改善瑞士儿童的个性化护理和证据生成.
科学领域:
- 儿科医疗保健研究的研究.
- 数字健康转型的数字化转型
- 个性化医疗基础设施 个性化医疗基础设施
背景情况:
- 对于儿科手术的有限证据基础需要改进数据生成.
- 数字化转型为数据驱动,个性化的儿科护理提供了机会.
- 瑞士PedHealth网络解决了迫切需要更好的儿科医疗保健提供.
研究的目的:
- 在瑞士建立一个可持续和可扩展的儿科临床数据基础设施.
- 为了使常规儿科临床数据可互操作,标准化和质量控制.
- 为观察性研究,质量保证,临床试验和卫生政策制定准备数据.
主要方法:
- 在2022年9月启动,由SPHN和PHRT共同资助.
- 开发模块化治理和监管策略,利用SPHN自动化程序.
- 涉及一个多站点,多学科的指导委员会与患者和家庭代表.
- 包括数据标准化,可行性测试,罕见疾病多学科整合和公众/患者参与等工作包.
主要成果:
- 卫生数据库条例已被伦理委员会 (AO_2022-00018) 批准.
- 该网络正在开发标准化的数据收集和集成方法.
- 目前正在进行初步项目,以测试数据流的可行性和实用性.
- 与家庭的接触和生物伦理学被整合到该项目中.
结论:
- 瑞士PedHealth正在瑞士建立数据驱动的儿科研究的基本基础设施.
- 该网络旨在加强针对儿童的个性化护理和证据生成.
- 标准化,可互操作的数据将支持研究,质量改进和政策制定.
相关概念视频
01:23Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
01:17Pharmacokinetics in Pediatric Patients: Drug Distribution
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...